第95回日本細菌学会総会

講演情報

シンポジウム

[S8] シンポジウム8
抗体医薬を用いた感染制御戦略

2022年3月31日(木) 09:15 〜 11:45 チャンネル3

コンビーナー:松村 拓大(金沢大学),小田 真隆(京都薬科大学)

[S8-4] ボツリヌス神経毒素を利用した神経細胞への抗体送達によるボツリヌス中毒の治療

宮下 慎一郎1,Jie Zhang2,Sicai Zhang2,3,相根 義昌1,Charles Shoemaker4,Min Dong2,3 (1東京農大・生物産業・食香粧化学,2Dept. Urol, Boston Child. Hosp.,3Dept. Surg., Dept. Microbiol., Harvard Med. Sch.,4Dept. Infect. Dis. Glo. Health, Cummings Sch. Vet. Med. Tufts Univ.)

Delivering therapeutics into the cytosol of the cell is challenging due to the cell membrane barrier. Bacterial toxins bind to the target cells and efficiently deliver their cargo into the cytosol. Here we took advantage of the ability of the toxins as a vehicle to deliver the therapeutics. Botulinum neurotoxins (BoNTs) specifically target and enter motor neurons, and block neurotransmitter release, resulting cause flaccid muscle paralysis known as botulism. BoNTs has an extremely long half-life within the neuron and induces paralysis that lasts for several weeks to months. Antiserum therapy is used to treat botulism, but they can neutralize only before toxins enter neurons. Our delivery platform is an atoxic chimeric toxin, which fused the receptor-binding domain of BoNT with the translocation domain and the catalytically inactivated catalytic domain of BoNT-like toxin BoNT/X. Single-domain antibody (VHH) against BoNT was fused to the chimeric-toxin and produced by E. coli. In vitro validation, the chimeric toxins delivered the VHH into the neuron and neutralized active BoNT in the cytosol. Furthermore, administration of VHH-chimeric toxin shortens the duration of muscle paralysis in a sub-lethal dose of BoNT injected mice, and rescued mice from lethal doses of BoNT. These results provide novel treatment for botulism and establish a platform to target intracellular proteins.